Technical Report abstract
Nature Genetics 39, 914 - 921 (2007)
Published online: 17 June 2007 | doi:10.1038/ng2045
Tissue-specific and reversible RNA interference in transgenic mice
Ross A Dickins1,3, Katherine McJunkin2,3, Eva Hernando4, Prem K Premsrirut3, Valery Krizhanovsky3, Darren J Burgess2,3, Sang Yong Kim3, Carlos Cordon-Cardo4, Lars Zender3, Gregory J Hannon1,2,3 & Scott W Lowe1,2,3
Abstract
Genetically engineered mice provide powerful tools for understanding mammalian gene function. These models traditionally rely on gene overexpression from transgenes or targeted, irreversible gene mutation. By adapting the tetracycline (tet)-responsive system previously used for gene overexpression, we have developed a simple transgenic system to reversibly control endogenous gene expression using RNA interference (RNAi) in mice. Transgenic mice harboring a tet-responsive RNA polymerase II promoter driving a microRNA-based short hairpin RNA targeting the tumor suppressor Trp53 reversibly express short hairpin RNA when crossed with existing mouse strains expressing general or tissue-specific 'tet-on' or 'tet-off' transactivators. Reversible Trp53 knockdown can be achieved in several tissues, and restoring Trp53 expression in lymphomas whose development is promoted by Trp53 knockdown leads to tumor regression. By leaving the target gene unaltered, this approach permits tissue-specific, reversible regulation of endogenous gene expression in vivo, with potential broad application in basic biology and drug target validation.
- Howard Hughes Medical Institute, Cold Spring Harbor, New York 11724, USA.
- Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
- Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA.
- Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Correspondence to: Scott W Lowe1,2,3 e-mail: lowe@cshl.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responsesThe EMBO Journal Article (11 Jul 2007)
Probing tumor phenotypes using stable and regulated synthetic microRNA precursorsNature Genetics Technical Report (01 Nov 2005)
New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivoGene Therapy Research Article
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYCNature Medicine Article (01 Jul 2007)
See all 72 matches for Research
